The cost, which is confidential and was negotiated for all in all , 300 huge number of doses, is slightly lower than the $19.50 per picture the United States agreed to pay for a very first shipment of hundred million doses of the same vaccine, in series with what Reuters claimed in November.
The EU file dated Nov. 18 was circulated internally right after the EU announced its supply package with Pfizer and its German partner BioNTech on Nov. 11.
The EU drug regulator is actually anticipated to decide on Monday on approval for the Pfizer vaccine after the shot was authorised in several countries, like Britain and the United States.
On Thursday Belgian declare secretary with the spending budget Eva De Bleeker released on Twitter a table with costs Belgium would spend pharmaceutical companies for the COVID-19 vaccines of theirs. She retracted the post shortly after posting.
In that dinner table the Pfizer vaccine was indicated as costing Belgium 12 euros ($14.6) a dose, leading many to believe that was the full fee agreed by way of the EU.
Other vaccines in the table were additionally shown with prices lower than rates disclosed by EU solutions.
“There is , obviously , a complete fee and a price upon delivery,” an EU official involved in talks with vaccine makers told Reuters when directed to clarify the big difference between the EU and Belgian rates.
A spokesman for De Bleeker declined to comment on Monday, citing confidentiality requirements, but pointed to what De Bleeker told the Belgian parliament last week. In this public hearing, De Beeker stated Belgium’s budgeted price tags were still partial.
Under EU advanced purchase deals for COVID 19 vaccines, the bloc believes initial payments with business enterprises to secure doses before they’re approved. Following approvals, EU governments are able to pay the remainder to get reserved doses.
The EU hasn’t revealed the upfront transaction agreed with Pfizer.
However, it stated in October that it paid aproximatelly one billion euros in downpayments to AstraZeneca, Sanofi and Johnson and Johnson for the shots of theirs, with an additional 1.45 billion euros budgeted for initial payments to Pfizer BioNTech, Curevac and Moderna.
It’s since agreed source deals with all six corporations and is negotiating a seventh understanding with Novavax.